| Autor: |
Henig I; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa 3109601, Israel., Isenberg J; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa 3109601, Israel., Yehudai-Ofir D; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa 3109601, Israel.; Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 3200003, Israel., Leiba R; Department of Statistics, Rambam Health Care Campus, Haifa 3109601, Israel., Ringelstein-Harlev S; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa 3109601, Israel.; Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 3200003, Israel., Ram R; Bone Marrow Transplantation Unit, Sourasky Medical Center, Tel Aviv 6423906, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel., Avni B; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Jerusalem 9112001, Israel.; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9190401, Israel., Amit O; Bone Marrow Transplantation Unit, Sourasky Medical Center, Tel Aviv 6423906, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel., Grisariu S; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Jerusalem 9112001, Israel.; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9190401, Israel., Azoulay T; Hematology Laboratory, Rambam Health Care Campus, Haifa 3109601, Israel., Slouzkey I; Hematology Laboratory, Rambam Health Care Campus, Haifa 3109601, Israel., Zuckerman T; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa 3109601, Israel.; Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 3200003, Israel. |
| Abstrakt: |
COVID-19-related mortality among hematopoietic stem cell transplantation (HSCT) recipients in the pre-vaccine era ranged between 22 and 33%. The Pfizer/BioNTech BNT162b2 vaccine demonstrated significant immunogenicity and efficacy in the healthy population; however, its long-term effects on allogeneic HSCT recipients remained unclear. Our study longitudinally evaluated humoral and cellular responses to the BNT162b2 vaccine in adult allogeneic HSCT patients. A positive response was defined as antibody titers ≥ 150 AU/mL post-second vaccination. Among 77 included patients, 51 (66.2%) responded to vaccination. Response-associated factors were female gender, recent anti-CD20 therapy, and a longer interval between transplant and vaccination. Response rates reached 83.7% in patients vaccinated >12 months post-transplant. At 6 months post-second vaccination, antibody titers dropped, but were significantly increased with the booster dose. Moreover, 43% (6/14) of non-responders to the second vaccination acquired sufficient antibody titers after booster administration, resulting in an overall response rate of 79.5% for the entire cohort. The BNT162b2 vaccine was effective in allogeneic transplant recipients. Although antibody titers decreased with time, the third vaccination led to their significant elevation, with 93% of third-dose responders maintaining titers above 150 AU/mL at 3 months post-administration. |
